Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab with chemoradiotherapy in locally advanced ESCC
NCT04602013Phase 2Unknown
- Sponsor
- Sichuan Cancer Hospital
- Start
- Oct 2020
- Primary completion
- May 2022
- Countries
- 1
01
Overview
Phase 2, open-label trial of sintilimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Sichuan Cancer Hospital. Primary endpoint: Progression-Free Survival at 3 years. Status: unknown.
02
Drugs
sintilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04602013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04602013.